Status:
COMPLETED
Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease
Lead Sponsor:
Shire
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess phosphate reduction and control in patients with End Stage Renal Disease treated with either lanthanum carbonate or sevelamer hydrochloride
Eligibility Criteria
Inclusion
- Patients receiving haemodialysis for ESRD
- Patients must have received haemodialysis for chronic renal failure three times per week for at least the previous 2 months
Exclusion
- Pregnant or lactating women
- Patients with clinically significant uncontrolled concurrent illness, a life-threatening malignancy or current multiple myeloma
- Patients who are HIV+
- Patients with any significant bowel obstruction, active inflammatory bowel disease, GI motility disorders, or a history of major GI surgery within the last 6 months
Key Trial Info
Start Date :
January 7 2005
Trial Type :
INTERVENTIONAL
End Date :
August 22 2005
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00151918
Start Date
January 7 2005
End Date
August 22 2005
Last Update
July 6 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.